Clinical trials: Preclinical Alzheimer's Disease
Alzheimer Disease, Mild Cognitive Impairment
Flortaucipir PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's Disease
A Phase 1 study designed to evaluate imaging characteristics of flortaucipir in the preclinical, prodromal and dementia phases of Alzheimer's disease.
- Trial name
- NCT04468347
- Testing
- Flortaucipir F18, Brain PET scan
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer Disease
Biomarkers for Monitoring Dementia Progression
The variable course of Alzheimer's disease (AD) and the paucity of adequate cures urges to implement new strategies for its early detection and clinical intervention.
- Trial name
- ADvance (NCT06855368)
- Where
- 2 sites in Italy
- Volunteers
- 300 people
- Sponsor
- IRCCS San Raffaele Roma
Sleep Disturbances, Aging
Low-intensity Hippocampal Transcranial Ultrasound Stimulation for Managing Cognitive and Sleep Dysfunction in Preclinical Alzheimer's Disease
Background: Sleep disturbances, as a common symptom, can jeopardize the brain health and cognitive function and even lead to cognitive impairments in older adults.
- Conditions
- Sleep Disturbances, Aging, Cognitive Impairment, Mild
- Trial name
- NCT07298876
- Testing
- Low-intensity transcranial ultrasound stimulation
- Where
- Hong Kong
- Volunteers
- 20 people
- Sponsor
- Chinese University of Hong Kong
Healthy, Cognitive Function 1, Social
Active Gains in Brain Using Exercise During Aging
AGUEDA (Active Gains in brain using Exercise During Aging) is a randomized controlled trial designed to examine the effects of a 24-week resistance exercise program on brain health in cognitively normal adults between 65-80 years…
- Trial name
- AGUEDA (NCT05186090)
- Testing
- 24-week resistance exercise program
- Where
- Spain
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Universidad de Granada
Preclinical Alzheimer's Disease
Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease
The purpose of this study is to assess the safety and efficacy of gemfibrozil in modulating microRNA-107 levels for the prevention of Alzheimer's disease in subjects with intact cognition and mild cognitive impairment
- Trial name
- NCT02045056
- Testing
- Gemfibrozil
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Gregory Jicha, 323-5550
APOE 4
Network-Level Mechanisms for Preclinical Alzheimer's Disease Development
The purpose of this project is to test the hypothesis that AGB101 low dose levetiracetam extended release formulation can reduce abnormal hyperfunctional activity in the hippocampus in normal, healthy adults.
- Trial name
- NCT03461861
- Testing
- AGB101 220 mg
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Medical College of Wisconsin
Alzheimer's Disease
Alzheimer's Prevention Through Exercise
The purpose of this study is to learn about the possible benefits of aerobic exercise in controlling or reducing the amount of amyloid present in the brain, reducing changes in brain structure that may lead to Alzheimer's Disease…
- Trial name
- APEx (NCT02000583)
- Testing
- Aerobic Exercise, Standard of Care
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- University of Kansas Medical Center
Alzheimers Disease
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.
- Trial name
- TRAVELLER (NCT07177352)
- Testing
- No Intervention
- Where
- 234 sites in United States, Argentina and 13 more
- Volunteers
- 80,000 people
- Sponsor
- Hoffmann-La Roche
Alzheimers Disease
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
The purpose of this study was to test whether two investigational drugs called CAD106 and CNP520, administered separately, could slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in…
- Trial name
- GS1 (NCT02565511)
- Testing
- CAD106 Immunotherapy, CNP520, Alum
- Where
- 129 sites in United States, Australia and 8 more
- Volunteers
- 480 people
- Sponsor
- Novartis Pharmaceuticals
Fall, Alzheimer Disease
Falls: A Marker of Preclinical AD
This longitudinal cohort study investigates cognitively normal participants with and without preclinical Alzheimer disease (AD) in order to examine: (1) the relationship between falls and functional mobility in preclinical stages…
- Trial name
- NCT04949529
- Where
- United States
- Volunteers
- 355 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Alzheimer Disease, Alzheimer Disease (AD)
DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau
This Phase 1 study will test the safety and immune response of the investigational vaccine DUVAX in healthy adults. Participants will be randomly assigned to receive either DUVAX or placebo by intramuscular injection.
- Conditions
- Alzheimer Disease, Alzheimer Disease (AD), Preclinical Alzheimer's Disease
- Trial name
- DU-PRISM (NCT07142278)
- Testing
- DUVAX 200 µg, DUVAX 400 µg
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Nuravax, Inc.
Alzheimer Disease, Mild Cognitive Impairment (MCI)
Communication Regarding Preclinical Dementia Diagnostic and Diagnostic Disclosure Among Patients with MCI and SCD
The study investigate what information individuals with SCD or MCI and their co-participant would like to receive during pre-diagnostic counseling and diagnostic disclosure, and how this information should be conveyed.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD)
- Trial name
- NCT06621758
- Testing
- questionnaire
- Volunteers
- 120 people
- Sponsor
- Danish Dementia Research Centre
Alzheimer Disease, Dementia
TapTalkTest Project:Development of a Non-invasive Screening Test to Detect Risk of Alzheimer's Disease Pathology
This project aims to produce a solution for the rising incidence of dementia. This is particularly pertinent in Tasmania, Australia, with a rapidly ageing population and the oldest demographics of all Australian states.
- Conditions
- Alzheimer Disease, Dementia, Movement Abnormalities, Speech Disorders
- Trial name
- TapTalkTest (NCT06114914)
- Testing
- Tap Talk online program
- Where
- Australia
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University of Tasmania
Alzheimer Disease
Effects and Mechanisms of Temporal Interference Brain Stimulation on Memory Function in Preclinical Alzheimer's Disease
The goal of this clinical trial is to learn if personalized, multimodal imaging-guided, EEG-based closed-loop Temporal Interference Brain Stimulation (TIBS) can improve memory function in individuals with preclinical Alzheimer's…
- Trial name
- NCT07031687
- Testing
- Active TIBS
- Where
- 2 sites in China
- Volunteers
- 1,200 people
- Sponsor
- Xuanwu Hospital, Beijing
Healthy Individuals
Study for Cognitive and Genetic Characterization of a 45-65 Years Old Population
Before Alzheimer's disease (AD) clinical symptoms appear, there is a long period when changes in the brain occur. In this long asymptomatic period or preclinical phase, studies with populations at risk of developing AD have shown…
- Trial name
- NCT01835717
- Where
- Spain
- Volunteers
- 2,743 people, healthy volunteers welcome
- Sponsor
- Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Alzheimer Disease, Cognitive Dysfunction, Cognitive Disorder
DIV-AD BARCELONA: Alzheimer's Blood-Based Biomakers for a Diverse Community
The DIV-AD study aims to find out whether levels of Alzheimer's disease markers in blood differ among the main ethnical groups living in central Barcelona.
- Conditions
- Alzheimer Disease, Cognitive Dysfunction, Cognitive Disorder, Dementia, Neurodegenerative Disease
- Trial name
- DIV-AD (NCT07521722)
- Where
- Spain
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Alzheimer Disease, Mild Cognitive Impairment
Atlas of Retinal Imaging in Alzheimer's Study
The Atlas of Retinal Imaging in Alzheimer's (ARIAS) study is a 5-year study examining the natural history of retinal imaging biomarkers associated with disease risk, disease burden, and disease progression in Alzheimer's disease…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia, Aging
- Trial name
- ARIAS (NCT03862222)
- Testing
- Retinal Imaging, Pupillometry, Contrast Sensitivity
- Where
- 4 sites in United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- University of Rhode Island
Alzheimer Disease, Subjective Cognitive Decline
Neurofeedback Intervention for Preclinical Alzheimer's Disease
Alzheimer's disease (AD) is the most common form of neurodegenerative disorders leading to dementia. Currently, there has been no effective pharmacologic therapy for this disease.
- Conditions
- Alzheimer Disease, Subjective Cognitive Decline, Neurofeedback, Electroencephalogram
- Trial name
- NCT04300933
- Testing
- Electroencephalogram-based neurofeedback
- Where
- China
- Volunteers
- 50 people
- Sponsor
- XuanwuH 2
Depression, Drive
Depression and Driving
This project will assess how depression, preclinical AD, and antidepressants affect driving behavior in cognitively normal older adults (65 years).
- Trial name
- D&D (NCT05446805)
- Testing
- F 18 AV-1451 (Flortaucipir), [11C]-Pittsburgh Compound B ([11C]PiB)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Washington University School of Medicine
Anhedonia in Healthy Volunteers, Older Adults (50-90 Years)
A Study of Psychedelics in Healthy Older Adults With Low Well-being
This study is being conducted to understand changes in brain activity following administration of two different drugs (Psilocybin and Dextromethorphan) in older adults with low well-being.
- Trial name
- OAD1 (NCT07386730)
- Testing
- Psilocybin (drug), Dextromethorphan (DXM)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Jennifer Mitchell